# A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema

> **NCT01100307** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 243 (actual)

## Conditions studied

- Macular Edema
- Diabetic Mellitus
- Retinal Disease

## Interventions

- **DRUG:** pegaptanib sodium
- **OTHER:** sham injection

## Key facts

- **NCT ID:** NCT01100307
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 243 (ACTUAL)
- **Last updated:** 2013-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01100307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01100307, "A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01100307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*